MedTrace Logo

Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)

NCT01960790 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 473

Last updated 2019-03-22

Study results available
· View outcomes & findings →

Summary

This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease.

1. Incidence and conditions of occurrence of adverse reactions in clinical practice
2. Factors likely to affect the safety and effectiveness

Conditions

  • Behcet's Disease

Sponsors & Collaborators

Principal Investigators

  • Osamu Mikami, MD · AbbVie

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-25
Primary Completion
2017-05-15
Completion
2017-05-15

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01960790 on ClinicalTrials.gov